Literature DB >> 33773871

Immune Checkpoint Inhibitors in Metastatic Clear-cell Renal Cell Carcinoma: Is PD-L1 Expression Useful?

Laurence Albiges1, Ronan Flippot2, Bernard Escudier2.   

Abstract

Entities:  

Year:  2021        PMID: 33773871     DOI: 10.1016/j.eururo.2021.02.040

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  4 in total

1.  Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma.

Authors:  Thomas Denize; Yue Hou; Jean-Christophe Pignon; Emily Walton; Destiny J West; Gordon J Freeman; David A Braun; Catherine J Wu; Saurabh Gupta; Robert J Motzer; Michael B Atkins; David McDermott; Toni K Choueiri; Sachet A Shukla; Sabina Signoretti
Journal:  Clin Cancer Res       Date:  2022-09-15       Impact factor: 13.801

2.  Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab.

Authors:  Johanna Noel; Anne Jouinot; Jérôme Alexandre; Guillaume Ulmann; Marie Bretagne; Zahra Castel-Ajgal; Sixtine De Percin; Clémentine Vaquin-Villeminey; Marie-Pierre Revel; Michael Peyromaure; Pascaline Boudou-Rouquette; Jennifer Arrondeau; Ithar Gataa; Jean-Philippe Durand; François Goldwasser; Olivier Huillard
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

3.  Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study.

Authors:  Lucia Carril-Ajuria; Aude Desnoyer; Laurence Albiges; Nathalie Chaput-Gras; Maxime Meylan; Cécile Dalban; Marie Naigeon; Lydie Cassard; Yann Vano; Nathalie Rioux-Leclercq; Salem Chouaib; Benoit Beuselinck; Sylvie Chabaud; Janice Barros-Monteiro; Antoine Bougoüin; Guillaume Lacroix; Irelka Colina-Moreno; Florence Tantot; Lisa Boselli; Caroline De Oliveira; Wolf Herve Fridman; Bernard Escudier; Catherine Sautes-Fridman
Journal:  J Immunother Cancer       Date:  2022-05       Impact factor: 12.469

Review 4.  New Therapeutic Interventions for Kidney Carcinoma: Looking to the Future.

Authors:  Lucio Dell'Atti; Nicoletta Bianchi; Gianluca Aguiari
Journal:  Cancers (Basel)       Date:  2022-07-25       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.